JB Pharma outlines key ESG goals & targets in Third Sustainability Report FY24
JB’s absolute Scope1 & Scope2 emissions reduced by 13.9 % in the last financial year, despite turnover increasing by 11%
JB’s absolute Scope1 & Scope2 emissions reduced by 13.9 % in the last financial year, despite turnover increasing by 11%
The first phase of the Aptivate Achi Bhookh Fest reached over 8,200 households
The share subscription agreements are being executed at a pre-money equity value of US$ 1.65 billion
Akums Drugs will undertake this development and commercialization in India
India has been declared ‘functional’ against all the core regulatory functions of the WHO Global Benchmarking Tool Version VI
Strokes are affecting approximately 1.8 million people annually
Indoco is comprehensively working on the remedial action plan
Strategic focus on COCO-model with a nationwide reach of 501 stores
Poor oral health (periodontal disease) impacts nearly 51% of Indians
The report highlights Piramal Pharma’s approach across four key strategic pillars: Responsible Operations, Business Resilience, Customer Centricity, and Quality & Excellence
Subscribe To Our Newsletter & Stay Updated